On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA ... a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic ...

Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly seems to have responded to the threat by President Donald Trump of tariffs on the pharma industry if they don't relocate their manufacturing operations to the US. The pharma group has ...

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright ...